Hypofractionated Radiotherapy in Localized, Low-Intermediate-Risk Prostate Cancer: Current and Future Prospectives.
Maria Chiara Lo GrecoGiulia MarlettaGiorgia MaranoAlessandro FazioEmanuele BuffettinoArianna IudicaRocco Luca Emanuele LiardoRoberto MilazzottoPietro Valerio FotiStefano PalmucciAntonio BasileFrancesco MarlettaFrancesco CucciaGiuseppe FerreraSilvana ParisiAntonio PontorieroStefano PergolizziCorrado SpatolaPublished in: Medicina (Kaunas, Lithuania) (2023)
At the time of diagnosis, the vast majority of prostate carcinoma patients have a clinically localized form of the disease, with most of them presenting with low- or intermediate-risk prostate cancer. In this setting, various curative-intent alternatives are available, including surgery, external beam radiotherapy and brachytherapy. Randomized clinical trials have demonstrated that moderate hypofractionated radiotherapy can be considered as a valid alternative strategy for localized prostate cancer. High-dose-rate brachytherapy can be administered according to different schedules. Proton beam radiotherapy represents a promising strategy, but further studies are needed to make it more affordable and accessible. At the moment, new technologies such as MRI-guided radiotherapy remain in early stages, but their potential abilities are very promising.
Keyphrases
- prostate cancer
- radiation therapy
- locally advanced
- high dose
- early stage
- radical prostatectomy
- radiation induced
- rectal cancer
- end stage renal disease
- squamous cell carcinoma
- low dose
- prognostic factors
- chronic kidney disease
- minimally invasive
- magnetic resonance imaging
- newly diagnosed
- stem cell transplantation
- ejection fraction
- clinical trial
- peritoneal dialysis
- small cell lung cancer
- high intensity
- double blind
- human health
- benign prostatic hyperplasia